Physician profile
Bobak Salami
NPI 1891700340
$5,945.05
in general payments reported to CMS, 2019-2025
36 companies · $777 in 2025
The $777 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $757 · 2021: $1,007 · 2022: $1,115 · 2023: $820 · 2024: $781 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,377.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $781.93 | 2019-2024 | Lifevest |
| Amgen INC. | $727.12 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $596.53 | 2019-2025 | |
| Medtronic, INC. | $413.81 | 2021-2025 | Cobalt Dr Mri Surescan, Corevalve Evolut R, Micra |
| Philips North America LLC | $391.46 | 2021-2024 | (5044) Mcot, (Ck4) Mcot |
| Pfizer INC. | $337.58 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $282.46 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $262.29 | 2019-2025 | Brilinta, Andexxa, Farxiga |
| Abbott Laboratories | $230.58 | 2019-2025 | Na, Amplatzer Amulet, Mitraclip |
| Janssen Pharmaceuticals, INC | $205.72 | 2019-2023 | Xarelto |
| Heartflow, INC. | $190.13 | 2019-2025 | |
| Boston Scientific Corporation | $187.21 | 2021-2025 | Farapulse, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.48 | 2021-2022 | |
| Esperion Therapeutics, INC. | $115.68 | 2021-2024 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $105.07 | 2021-2023 | Arcalyst |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $101.48 | 2019-2025 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $86.98 | 2022-2023 | Verquvo |
| Novo Nordisk INC | $76.46 | 2024-2025 | Ozempic, Rybelsus |
| Zoll Circulation INC | $67.62 | 2020 | |
| Astellas Pharma US INC | $57.06 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.86 | 2021-2024 | |
| Medtronic Vascular, INC. | $53.29 | 2020 | |
| Biosense Webster, INC. | $52.01 | 2025 | Nuvision Ice Catheter |
| Akcea Therapeutics, INC. | $45.82 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $43.93 | 2020-2022 | |
| Amarin Pharma, INC. | $42.11 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $41.48 | 2019-2021 | |
| Cleerly, INC. | $38.75 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Kiniksa Pharmaceuticals International, Plc | $36.35 | 2024 | Arcalyst |
| Teleflex LLC | $36.06 | 2023 | Quikclot |
| Baxter Healthcare | $35.22 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Cvrx, INC. | $31.48 | 2025 | Barostim Neo System |
| Chiesi USA, INC. | $25.50 | 2023 | Kengreal, Cleviprex |
| Alnylam Pharmaceuticals INC. | $14.68 | 2020 | |
| Cardiovascular Systems INC. | $14.11 | 2021 | |
| Angiodynamics, INC. | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobak Salami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.